Association Between Blood Eosinophils and Neutrophils With Clinical Features in Adult-Onset Asthma

Flinkman, Ella; Vähätalo, Iida; Tuomisto, Leena E.; Lehtimäki, Lauri; Nieminen, Pentti; Niemelä, Onni; Hämäläinen, Mari; Moilanen, Eeva; Kankaanranta, Hannu; Ilmarinen, Pinja

doi:10.1016/j.jaip.2022.11.025

Cited by 15 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Тяжка форма нейтрофільної БА, яка, як правило, характеризується хронічним запаленням дихальних шляхів, рефрактерним до кортикостероїдів, вимагає більш глибоких досліджень, оскільки її патогенез недостатньо вивчений, тому й не існує ефективного лікування пацієнтів [5,6]. Кількість еозинофілів та нейтрофілів у крові відображає основні запальні закономірності та може вказувати на важливі відмінності в клінічних ознаках БА та опосередковано диференціювати фенотипи БА у дорослих [7]. Хоча місцева інфільтрація еозинофілами і тучними клітинами та їх роль у захворюванні давно визнані, нейтрофільна інфільтрація також оцінюється в багатьох клінічних дослідженнях, де нейтрофільоз дихальних шляхів пов'язують з тяжкістю БА.…”

Section: особливості локального та системного запалення при бронхіаль...unclassified

Current Views on the Role of the Pro-Inflammatory Cytokine IL-26 in the Development and Clinical Course of Bronchial Asthma Associated with Obesity and Treatment Strategy

Avramenko,

Kaidashev

2023

View full text Add to dashboard Cite

Abstract. In Ukraine and the world, the incidence of bronchial asthma (BA) and obesity among children and adults is simultaneously increasing, which is a serious problem of public health and health care management. Modern research links both diseases. The aim: To analyze the pathogenetic relationship between BA and obesity, to formulate a clinical understanding, the pathophysiology of asthma and obesity phenotypes, the impact and effectiveness of strategies for the treatment of obesity and obesity in combination with BA. Materials and methods. Analytical review of scientific publications by topic was performed using the databases of scientific libraries, search engines Google Scholar, Pub Med, Science Direct, etc. Results. To date, various hypotheses have been proposed to explain the association between obesity and asthma, such as a general genetic predisposition, impaired body development, altered respiratory mechanics, the presence of a systemic inflammatory process, and an increased prevalence of comorbidities in this cohort of patients. Patients with obesity and BA have more symptoms, a more severe course of BA, insufficient effectiveness of standard treatment, progressive deterioration of the quality of life. Despite more than a decade of research into the association between these diseases, the exact mechanisms underlying the interaction between obesity and asthma remain largely unclear and require further study. Understanding the mechanism of the association between obesity and asthma may lead to the development of new effective therapeutic strategies for the treatment of this sensitive population. Conclusions. The prevalence of the disease, the economic costs of treatment and its ineffectiveness require further scientific research in this direction. It is necessary to determine the role of new biomarkers, including IL-26, in the development and clinical course of BA in combination with obesity and to improve the effectiveness of treatment of such patients.

show abstract

Section: особливості локального та системного запалення при бронхіаль...unclassified

Current Views on the Role of the Pro-Inflammatory Cytokine IL-26 in the Development and Clinical Course of Bronchial Asthma Associated with Obesity and Treatment Strategy

Avramenko,

Kaidashev

2023

View full text Add to dashboard Cite

show abstract

“… 11 , 12 In addition, patients with asthma with high blood eosinophil counts had more nasal polyps, a greater decline in lung function, higher levels of serum IgE and of fractional exhaled nitric oxide (FeNO), all biomarkers of T2 inflammation. 13 In clinical practice, serum IgE levels are used to identify the allergic asthma phenotype whilst current or historical blood eosinophil counts above 150–300/μL and FeNO levels of ≥25 ppb are used to indicate eosinophilic or T2 asthma. 14 , 15 , 16 …”

Section: Introductionmentioning

confidence: 99%

“… 17 A study of neutrophilic asthma defined by raised blood neutrophil count with low blood eosinophil counts, found that this was associated with increased levels of C-reactive protein, matrix metalloproteinase-9, IL-6, leptin, and soluble urokinase plasminogen activator receptor serum levels. 13 This non-T2 or T2-low neutrophilic phenotype does not have any targeted biologic therapies since the key driving pathways are unclear. 18 There is a need for a more granular definition of asthma phenotypes using blood biomarkers not only to inform the underlying molecular pathways but also to facilitate personalised therapeutic choices.…”

Section: Introductionmentioning

confidence: 99%

“…In the present study, we used high-resolution proteomic profiles in 686 asthma participants with mild-moderate and severe disease from two cohorts to identify a set of serum proteins that would be predictive of either eosinophilic or neutrophilic asthma status as defined by the established clinical thresholds of granulocyte counts in both blood and sputum and investigate the underlying molecular pathways. 11 , 13 We compared the serum biomarkers identified and their predictive ability to that of sputum biomarkers obtained in a subset who provided both blood and sputum samples.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum

Asamoah,

Chung,

Zounemat Kermani

et al. 2024

eBioMedicine

View full text Add to dashboard Cite

“…In recent years, asthma phenotypes have been classified into two asthma endotypes: type-2 (T2)-high and T2-low [ 6 ]. The T2-high endotype is characterized by Th2-associated cytokines such as interleukin (IL)-4, IL-5, and IL-13 and elevated levels of eosinophils, serum periostin, and total immunoglobulin E (IgE) and includes allergic and eosinophilic asthma [ 7 , 8 ]. The T2-low endotype has no identified biomarkers or eosinophilic elevation and generally includes all patients with asthma without Th2-high inflammation [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Personalized Medicine in Severe Asthma: From Biomarkers to Biologics

Chen,

Wu,

Guo

et al. 2023

IJMS

View full text Add to dashboard Cite

Severe asthma is a complex and heterogeneous clinical condition presented as chronic inflammation of the airways. Conventional treatments are mainly focused on symptom control; however, there has been a shift towards personalized medicine. Identification of different phenotypes driven by complex pathobiological mechanisms (endotypes), especially those driven by type-2 (T2) inflammation, has led to improved treatment outcomes. Combining biomarkers with T2-targeting monoclonal antibodies is crucial for developing personalized treatment strategies. Several biological agents, including anti-immunoglobulin E, anti-interleukin-5, and anti-thymic stromal lymphopoietin/interleukin-4, have been approved for the treatment of severe asthma. These biological therapies have demonstrated efficacy in reducing asthma exacerbations, lowering eosinophil count, improving lung function, diminishing oral corticosteroid use, and improving the quality of life in selected patients. Severe asthma management is undergoing a profound transformation with the introduction of ongoing and future biological therapies. The availability of novel treatment options has facilitated the adoption of phenotype/endotype-specific approaches and disappearance of generic interventions. The transition towards precision medicine plays a crucial role in meticulously addressing the individual traits of asthma pathobiology. An era of tailored strategies has emerged, allowing for the successful targeting of immune-inflammatory responses that underlie uncontrolled T2-high asthma. These personalized approaches hold great promise for improving the overall efficacy and outcomes in the management of severe asthma. This article comprehensively reviews currently available biological agents and biomarkers for treating severe asthma. With the expanding repertoire of therapeutic options, it is becoming increasingly crucial to comprehend the influencing factors, understand the pathogenesis, and track treatment progress in severe asthma.

show abstract

Association Between Blood Eosinophils and Neutrophils With Clinical Features in Adult-Onset Asthma

Cited by 15 publications

References 39 publications

Current Views on the Role of the Pro-Inflammatory Cytokine IL-26 in the Development and Clinical Course of Bronchial Asthma Associated with Obesity and Treatment Strategy

Current Views on the Role of the Pro-Inflammatory Cytokine IL-26 in the Development and Clinical Course of Bronchial Asthma Associated with Obesity and Treatment Strategy

Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum

Personalized Medicine in Severe Asthma: From Biomarkers to Biologics

Contact Info

Product

Resources

About